Resource News

Grafoid Inc. has formed Calevia Inc., a joint venture partnership with ProScan RX Pharma Inc. to develop a graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors.

Grafoid Inc. has formed Calevia Inc., a joint venture partnership with ProScan RX Pharma Inc., to develop a graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors.

“Calevia sets a clear example to the world how graphene technologies serve humanity,” said Mr. Economo. “As a business, the MesoGraf™-based therapy we aim to bring to market leaves us well positioned with the potential to re-define the treatment for tumorous cancers.”

Mr. Economo said the Calevia partnership combines ProScan’s established cellular antibody targeting technologies with Grafoid’s MesoGraf™Xide graphene to eradicate cancerous cells in a non-invasive manner.

Calevia will first target prostate cancer using ProScan’s anti-PSMA antibody. The platform will be developed subsequently for several solid tumor types.

Grafoid’s MesoGraf™ derivative, MesoGraf™Xide is the latest development in thermal energy generating nanomaterial science that instantly transforms near infrared (NIR) light into heat.

“Grafoid’s move into the bio-medical nanotechnology sector is representative of MesoGraf’s versatility and its value in terms of its adaptability for use in virtually any industrial sector,” said Mr. Economo. “MesoGraf™,” he added, “sets the universal standard for graphene.”

Click here to read the Grafoid Inc. press release

See this press release on Marketwire
Click here to see the Grafoid Inc. profile.

MARKETS

Markets
TSX18762.68-315.96
TSXV613.58-12.76
DOW30681.12-348.19
S&P 5003776.25-42.58
NASD11012.41-165.48
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1808.94-9.88
Silver20.37-0.37
Copper3.71-0.07
Palladium1893.00-69.00
Platinum905.00-14.00
Oil106.63-3.15
Heating Oil3.79-0.16
Natural Gas5.90-0.59

DOWNLOAD FREE REPORTS

×